Gilead's bictegravir, lenacapavir tablet meets mark in phase 3
|
Gilead Sciences has developed an industry-leading HIV
portfolio in recent years with its megablockbuster daily treatment Biktarvy
and its new ... |
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.